Lv6
2050 积分 2024-01-12 加入
China rheumatoid arthritis registry of patients with Chinese medicine (CERTAIN): Rationale, design, and baseline characteristics of the first 11,764 enrollees
21天前
已完结
A new look at rheumatology in China—opportunities and challenges
22天前
已完结
Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future
30天前
已完结
Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategies
1个月前
已关闭
Myasthenia Gravis Impairment Index
4个月前
已完结
Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: A retrospective cohort study
6个月前
已完结
Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets
6个月前
已完结
Clinical characteristics of anti‐AChR‐MuSK‐LRP4 antibody‐negative myasthenia gravis in China
6个月前
已完结
Treatment of autoimmune myasthenia gravis
6个月前
已完结
Therapeutic options in autoimmune myasthenia gravis
6个月前
已完结
皖公网安备34019202002308
